Shenzhen Neoimmune Co., Ltd announced the completion of tens of millions of RMB in PreA financing.

2022-03-09 16:50:52 Neoimmune 51423

On November 2021, 11, Shenzhen Neoimmune Co., Ltd, a clinical immunology company, announced the completion of tens of millions of RMB PreA financing. This round of investment was funded by Kangsheng Global (25. HK) participated in the initiation, led by Ruijiang Kangsheng Fund managed by Ruijiang Investment, and co-investors included Spark Venture Capital and Changjiang Yuantong Fund. Shenzhen Neoimmune Co., Ltd has obtained the first domestic CE registration certificate for hematological tumor MRD (Minimal Residual Lesions), and this round of funds will be mainly used for the promotion of hematological tumor MRD products and the research and development of new clinical products.

图片关键词

MRD (Minimal Residual Disease) refers to the state of trace tumor cells left in the body after treatment for malignant tumors, which is the root cause of tumor recurrence. Accurate MRD detection is the basis for personalized precision medicine for patients, which can predict clinical outcomes, stratify the risk level of patients, and guide treatment decisions. To predict tumor recurrence early and determine the optimal time for bone marrow or stem cell transplantation. In March 2021, NEO-MRD, the first domestic hematological tumor MRD® detection product developed by Pan-Cause Medicine, obtained the EU CE access qualification. Based on the NGS platform, NEO-MRD® has the characteristics of high detection rate, high accuracy and automation, and can also monitor the emergence of new high-frequency clones and evaluate the reconstruction of the immune system, which can greatly contribute to the development of the global hematological tumor microresidual disease industry.

图片关键词

Shenzhen Neoimmune Co., LtdShenzhen Neoimmune Co., LtdShenzhen Neoimmune Co., LtdShenzhen Neoimmune Co., Ltd is a leading immunoomics technology platform company in China, the founding team has published the first domestic leukemia NGS MRD paper, has published more than 20 high-level immunomics papers, applied for more than 20 patents, and published many reports at the international/Chinese Immunology Academic Conference and the annual meeting of the International Alliance of ImmunizationGroups (AIRR Community). Professor Liu Xiao, founder of Shenzhen Neoimmune Co., Ltd, said that there are a large number of unmet patient needs in clinical immunodetection and treatment, and has built a complete platform from dry and wet experiments to functional verification around high-throughput immunomics, and is committed to developing clinical products for screening, diagnosis, prognosis and treatment of immune-related diseases,and has laid out scientific and technological services, clinical testing, immunotherapy and immune health. Xu Guowei, CEO of Shenzhen Neoimmune Co., Ltd, said that the company's PreA round of financing was favored by Kangsheng Global, and he was very grateful to Ruijiang Kangsheng Fund, Spark Capital and Changjiang Yuantong Fund for their recognition and support of the company's innovation capabilities and concepts. Through this collaboration, we will jointly explore and develop better detection technologies and immunotherapy drugs to serve patients and make life hopeful."

图片关键词

Huang Shiang, chairman of the board of directors of Kangsheng Global, introduced that the company will continue to actively build a cutting-edge technology platform in various forms to explore the future technology development direction of the clinical special examination industry. The company's strategic investment in Pan-Cause Medicine will make full use of the advantages of both parties in product research and development, data accumulation, sales channels and other aspects, so that Pan-Cause Medical products can be rapidly commercialized while further improving the product pipeline layout of Kangsheng Global. In addition, Huang Shiang pointed out that the clinical application of immune group library detection is very extensive, in addition to tumor MRD detection, it can also be used in autoimmune diseases, infectious diseases, transplantation and immune reconstitution, antibody development, drug use and vaccine evaluation, etc., this market is very large, and many excellent companies will emerge in this field in the future. In addition to investing in pan-cause medicine, Kangsheng Global is also actively cultivating and incubating immunological library projects for different application directions and exploring new technologies and businesses.

Zhao Jinqiang, chairman of Ruijiang Investment, said that the exclusive lead of the fund managed by Ruijiang Investment in Pan-Cause Medicine is the trust of the excellent team of Pan-Cause Medicine and the recognition of the future development of Pan-Cause Medicine in immunomics. Here, I would like to thank Kangsheng Global, a leading company in China's outstanding special inspection industry, for its support to Ruijiang Kangsheng Fund and Pan-Cause Medicine. We believe that with the joint efforts of the three parties, Pan-Cause Medicine can become one of the leaders in China in the field of immune platform construction and genetic testing and treatment. Discovering value, creating value, and creating infinite possibilities with outstanding entrepreneurs are the consistent tenets of Ruijiang Investment.

Dr. Xiaosheng Lu, Managing Partner of Spark Ventures, pointed out that the high-precision diagnosis of tumor MRD (minimal residual lesions) is very important for the evaluation of patients' treatment effects and subsequent treatment and rehabilitation. The high-precision diagnosis market segment of hematological tumor MRD has four core technologies, builds high barriers in the industry, and builds a leading clinical immunoassay platform enterprise in China against Adaptive, which will benefit the majority of cancer patients and families.

About Ruijiang Investment, a fund management company (managing Ruijiang Kangsheng Fund and Changjiang Yuantong Fund)

Founded in 2012, Ruijiang Investment is headquartered in Wuhan with branches and teams in Beijing, Shanghai, Chengdu and Hong Kong. The company's vision is to meet people's needs for a better life with high-quality financial services and products. The main business covers equity investment funds and industrial investment funds. Discovering value and creating value, walking with excellent entrepreneurs is our consistent philosophy.

The company's founder graduated from the University of Chicago, and the company's management team and investment team are composed of senior investors with international vision. Growth stage equity investment funds focus on medical, hard technology, environmental protection and education industries, the company currently manages 8 equity investment funds, including listed companies, fund of funds, family offices, etc.

About Spark Ventures

The core management team of Spark Ventures is derived from Spark UK, a leading professional venture capital management institution in Europe focusing on the investment of start-up and growth-stage technology-based enterprises, including the Magdalen College Fund of the University of Oxford, Prudential Insurance, European Government Investment Fund, General Electric Capital and other institutional investor funds.

About Shenzhen Neoimmune Co., Ltd

Shenzhen Neoimmune Co., Ltd. is a preferred supplier of data and technology in the field of immunology precision medicine, relying on immunological NGS technology to provide product solutions for the whole process of disease discovery, detection, monitoring and treatment. Committed to preventing the occurrence of major diseases, accurate detection in the diagnosis and treatment process and precise medication in the treatment process, so as to achieve the whole process of precision treatment coverage and improve the length of life.

About Kangsheng Global Gene Technology

Founded in 2003, Kangsheng Global Gene Technology Co., Ltd. is the first and leading independent clinical special examination service provider in China. At present, Kangsheng Global has established a leading position in China's independent hematology clinical examination industry, offering one of the world's most extensive hematology test portfolios. We provide a wide range of testing services to hospitals, contract research institutes and pharmaceutical companies, providing customers with a wide range of tests and customized high-quality special examinations in a cost-effective manner, helping doctors optimize diagnosis and choose personalized treatment plans for patients.

Contact Us

8/F, Block A, Hengtemei Building, No. 3 Ganli Road, Longgang District, Shenzhen; 402, Kelente R&D Building, Ganli Road, Longgang District, Shenzhen.

TEL: 0755-8453-4802

EMAIL

query@neoimmune.cn